Patient Experience Journal
Volume 5

Issue 3

Article 17

2018

Perceptions of patient-centered care among veterans with
gastroesophageal reflux disease on proton pump inhibitor therapy
Salva N. Balbale
Center for Evaluation of Practices and Experiences of Patient-centered Care (CEPEP) & Center of
Innovation for Complex Chronic Health Care (CINCCH), Edward Hines Jr. VA Hospital, Hines, IL, USA;
Division of Gastroenterology and Hepatology, Department of Medicine, & Center for Healthcare Studies,
Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago,
IL USA

Andrew Gawron
Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA; Division of Gastroenterology,
Hepatology, & Nutrition, University of Utah, Salt Lake City, UT, USA

Sherri L. LaVela PhD, MPH, MBA
Center for Evaluation of Practices and Experiences of Patient-centered Care (CEPEP) & Center of
Innovation for Complex Chronic Health Care (CINCCH), Edward Hines Jr. VA Hospital, Hines, IL, USA;
Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, Northwestern
University, Chicago, IL USA

Follow this and additional works at: https://pxjournal.org/journal
Part of the Health Services Research Commons

Recommended Citation
Balbale SN, Gawron A, LaVela SL. Perceptions of patient-centered care among veterans with
gastroesophageal reflux disease on proton pump inhibitor therapy. Patient Experience Journal. 2018;
5(3):149-159. doi: 10.35680/2372-0247.1232.

This Research is brought to you for free and open access by Patient Experience Journal. It has been accepted for
inclusion in Patient Experience Journal by an authorized editor of Patient Experience Journal.

Perceptions of patient-centered care among veterans with gastroesophageal
reflux disease on proton pump inhibitor therapy
Cover Page Footnote
ACKNOWLEDGMENTS Specific author contributions: Sherri LaVela, Andrew Gawron and Salva Balbale
planned and conducted the study. Salva Balbale and Andrew Gawron analyzed data. Salva Balbale drafted
the initial form and all revisions of this manuscript. All authors reviewed and approved the final
manuscript draft submitted. Financial support: This study was funded by the Department of Veterans
Affairs, Office of Patient-Centered Care and Cultural Transformation and the Office of Research and
Development Health Services Research and Development, Quality Enhancement Research Initiative
(PEC-13-002; PI: LaVela). The views expressed in this manuscript are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans Affairs. Potential competing
interests: None.

This research is available in Patient Experience Journal: https://pxjournal.org/journal/vol5/iss3/17

Patient Experience Journal
Volume 5, Issue 3 – 2018, pp. 149-159

Research

Perceptions of patient-centered care among veterans with gastroesophageal
reflux disease on proton pump inhibitor therapy

Salva N. Balbale, MS, Center for Evaluation of Practices and Experiences of Patient-centered Care (CEPEP) & Center of
Innovation for Complex Chronic Health Care (CINCCH), Edward Hines Jr. VA Hospital, Hines, IL, USA; Division of
Gastroenterology and Hepatology, Department of Medicine, & Center for Healthcare Studies, Institute for Public Health and
Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL USA
Andrew Gawron, MD, PhD, MS, Salt Lake City Veterans Affairs Medical Center, Salt Lake City, UT, USA;
Division of Gastroenterology, Hepatology, & Nutrition, University of Utah, Salt Lake City, UT, USA
Sherri L. LaVela, PhD, MPH, MBA, Center for Evaluation of Practices and Experiences of Patient-centered Care
(CEPEP) & Center of Innovation for Complex Chronic Health Care (CINCCH), Edward Hines Jr. VA Hospital, Hines,
IL, USA; Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, Northwestern University,
Chicago, IL USA
Abstract
The aim of this study was to explore perceptions of patient-centered care (PCC) among Veterans with gastroesophageal
reflux disease (GERD) on proton pump inhibitor (PPI) therapy using patient-reported outcome (PRO) measures. We
used three validated surveys to measure PCC concepts in a national sample of Veterans with GERD on PPI therapy.
The Combined Outcome Measure for Risk Communication and Treatment Decision Making Effectiveness
(COMRADE) measures patient experiences with risk communication and decision-making. The Patient Activation
Measure (PAM) evaluates confidence and knowledge needed for self-management. The Patient Assessment of Care for
Chronic Conditions (PACIC) assesses views of chronic care received. We used descriptive statistics to describe patient
characteristics and PCC outcomes. Respondents (n=444) were mostly male (95.1%) with a mean age of 67.7 years. The
mean COMRADE score measuring patient experiences with risk communication was 55.3 (SD=19.0). The mean PAM
score was 56.1 (SD=19.2); 47.8% of respondents were considered disengaged patients lacking confidence and knowledge
for self-management. The mean PACIC summary score was 3.03 (SD=1.2), with highest scores in the Delivery System
Design/Decision Support (3.38, SD=1.2) subscale, and lowest scores in the Follow-up/Coordination subscale (2.58,
SD=1.3). Veterans with GERD reported that care was well-organized and supportive in enhancing decision-making.
Potential gaps in patient experiences may exist in delivering follow-up care, enhancing patient activation, and informing
patients about risks of available GERD treatments. This is the first study to evaluate patient perceptions of PCC in a
national sample of Veterans with GERD on PPI therapy. Findings can inform further investigation and development of
targeted interventions to enhance the experience of PCC for individuals with GERD.
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Introduction
Gastroesophageal reflux disease (GERD) is a common
chronic condition that affects up to 28% of the North
American population.1 Among all digestive diseases in the
United States, GERD accounts for the highest direct
health care costs and represents the leading diagnosis in
the outpatient care setting.2-3 The disease is characterized
by a broad range of troublesome esophageal symptoms,
including heartburn, acid regurgitation, reflux esophagitis,
stricture, Barrett’s esophagus, and adenocarcinoma, as well
as several extraesophageal complications.4-5 In light of the
complex nature and increasing prevalence, there is

considerable variability around the impact of GERD
symptoms on patients.6-8
This variability extends into the delivery of chronic care
for individuals with GERD, where substantial differences
and gaps exist in establishing initial diagnoses,
coordinating follow-up care, and measuring quality of
care.9-11 Furthermore, a central challenge in caring for
individuals with GERD stems from treatment
management with proton pump inhibitor (PPI) therapy.
Although widely regarded as an effective treatment
strategy, numerous studies have highlighted trends of
inappropriate use and suboptimal dosing of PPI therapy. 1215 These patterns are problematic given the rising costs and
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documented health risks associated with long-term PPI
use,16-19 and given evidence that a significant proportion of
PPI users continues to experience breakthrough GERD
symptoms and reports lower levels of satisfaction with
treatment.9, 20
To enhance care for patients with GERD, a patient-centric
model may be especially beneficial. Patient-centered care
(PCC) calls for the redesign of health services to tailor care
around patient needs and preferences, enhance quality of
care, and integrate care processes.21 The model may be
well-suited for GERD care because of its individualized
approach to address complex, chronic diseases,22-23 its
emphasis on efficient and evidence-based care, and its
focus on patient engagement.24 In light of increased media
coverage around the risks of PPI treatment and
subsequently heightened patient concerns,25 patientcentered approaches that are responsive to individual
needs and preferences may be particularly helpful.
PCC is tied closely to patients’ experience of care.
Cornerstones of PCC—including understanding the
patient journey and providing personalized care—are
aligned with current definitions of the patient experience.26
These are increasingly important to consider given the
inclusion of patient experience as an indicator of quality
and performance within health care organizations.27 To
our knowledge, no published studies have focused on
patient experiences related to GERD, but these are needed
to understand and improve care around patients’ unique
needs. Measuring patient experiences can be challenging;
however, prior literature suggests that successful
approaches are centered on what matters most to
patients.28 Thus, PCC outcomes that focus on patient
views of their own care may offer a useful lens to study
patient experiences.
In the United States, the Veterans Affairs (VA) Health
Care System is one of many health care organizations to
adopt PCC.29 An essential component of PCC
implementation is obtaining patient-level evaluations of
care to better understand patient experiences and
outcomes.30 Deriving patient-reported insights, moreover,
is an important prerequisite for developing strategies that
enhance care in a way that aligns with the needs of patients
with GERD.31 Although patient-reported outcome (PRO)
measures have been used to assess clinical symptoms
among patients with GERD,32 few studies demonstrate the
use of PRO measures to describe PCC outcomes,
including experiences and perspectives around chronic
care delivery and organization, patient activation, decisionmaking, and self-management. In particular, limited data
exist that describe PCC outcomes among Veteran patients
with GERD on PPI therapy, yet this information is
needed to enhance the quality of PCC for an increasingly
large and diverse population affected by GERD. Our aim
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was to explore perceptions of PCC among Veteran
patients with GERD on PPI therapy using PRO measures.

Methods
Study Design and Respondents

The Center for Evaluation of Practices and Experiences of
Patient Centered Care (CEPEP) is a VA funded project
(PEC-13-002, PI: LaVela) to evaluate a range of PCC
outcomes across the VA Health Care System. As part of
this project, we conducted a cross-sectional mailed survey
of Veterans with GERD who received care from eight
nationally representative VA health care facilities across
the northeastern/mid-Atlantic, southeastern, southwestern
and western regions. During February and March 2013, we
mailed a cover letter describing the purpose of the study, a
survey, and a pre-paid VA business reply envelope to
eligible respondents. We performed a follow-up mailing of
the survey in mid-2013 to Veterans who had not
responded to the original mailing. We used VA
administrative databases to identify eligible respondents
and used stratified random sampling and Dillman’s sample
size selection equation33 to ensure adequate power and
generalizability of our findings to the broader Veteran
population.
Inclusion criteria for this study were Veteran patients with
a clinical outpatient diagnosis of GERD (ICD-9 codes:
530.81 and 530.11) who were prescribed PPI therapy
within 30 days following GERD diagnosis and who had
received health care from a VA facility during the prior 6
months. PPI doses (standard or high dose prescriptions)
were calculated as the ratio of quantity of
medication/day’s supply of medication at initial
prescription. Long-term PPI use was defined as six
months or more of therapy. We used VA administrative
databases to extract GERD and other chronic condition
data, as well as health care utilization information for a
one-year period (October 1, 2012 – September 30, 2013)
for all respondents.
This study was conducted as part of a larger quality
improvement effort by VA health care facilities to evaluate
PCC using methods that capture patient perspectives.

Survey Measures and Data Sources

The survey included questions on patient demographics
(age, sex, race, ethnicity, education), recent hospital or
doctor visits, and three validated PRO instruments that
assessed PCC outcome measures. These measures
included the (1) Combined Outcome Measure for Risk
Communication and Treatment Decision Making
Effectiveness (COMRADE), the (2) Patient Activation
Measure (PAM) instrument, and the (3) Patient
Assessment of Care for Chronic Conditions (PACIC).
Each measure is intended to capture key elements of the
patient experience,28 including patient-provider
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communication, decision making, patient involvement in
care, and coordination and continuity of care.
COMRADE. The COMRADE is a 20-item scale that
assesses levels of patient perception of effective risk
communication and confidence in shared decision-making
as it relates to medical treatment. The instrument subscales
include risk communication and decision-making
effectiveness and represent distinct shared decisionmaking constructs.34 The risk communication subscale
addresses the information exchange between patients and
providers around the potential risks and benefits of
treatment. The decision-making effectiveness subscale is
focused on the outcome of the information exchange and
decision-making processes.35 Items are evaluated on a 5point Likert scale (where 1=strongly disagree and
5=strongly agree). Overall COMRADE scores are defined
across a range of 0 to 100, where higher scores indicate
better communication and outcomes, as well as more
informed and effective decision-making.35
PAM. The short-form version of the PAM is a 13-item
instrument designed to measure the degree to which
patients are engaged in their health care and possess the
knowledge, skills and confidence needed for selfmanagement. The instrument helps generate a patient
activation score that places respondents into one of four
categories (levels 1-4), each representing an increasingly
higher level of activation.36 Using a Likert scale,
respondents are asked to evaluate their level of agreement
with statements reflecting the 4-step developmental
process of patient activation. Activation stages include
Stage 1: believing the patient role is important; Stage 2:
having the confidence, knowledge and skills needed to
take action; Stage 3: taking action to maintain selfmanagement; Stage 4: sustaining the course under stress.
PAM scores range from 1 to 100, where higher scores
indicate better skills, knowledge and behaviors necessary
for self-management as well as greater patient activation
along the four stages. Raw scores are converted into an
overall patient activation score and subsequently
interpreted using a table developed by Hibbard and
colleagues.36-37
PACIC. The PACIC is a 20-item instrument that assesses
patient perceptions of the chronic care received. The
instrument is organized into five subscales that address
elements of PCC as perceived by patients with chronic
illness; these subscales include Patient Activation, Delivery
System Design/Decision Support, Goal Setting, Problem
Solving/Contextual Counseling, and Followup/Coordination.38 Respondents are asked to evaluate
chronic care received over the last six months. Individual
PACIC items are scored on a 5-point Likert scale, where
1=no/never and 5=yes/always. The overall PACIC
summary score is the average of all 20 items. Subscales are
scored by averaging the values of responses corresponding
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to each subscale. Higher scores indicate higher or more
favorable perceptions of chronic care received in the last
six months.39

Statistical Analysis

All analyses were conducted using SAS software version
9.3 (SAS Institute Inc., Cary, NC). We used descriptive
statistics to characterize the overall sample and assess PCC
outcomes. We determined overall summary scores and
subscale scores for each survey measure among Veterans
diagnosed with GERD and prescribed PPI therapy.

Results
The surveys were mailed to 1,777 Veteran patients with a
GERD diagnosis who were prescribed PPIs. Of these, a
total of 41 surveys were undeliverable, 11 patients had
died, and 2 surveys were returned unopened or indicated
as ‘not applicable,’ leaving 1,723 Veterans. The survey was
completed by 444 Veteran patients (25.8% response rate)
who had complete survey data for the COMRADE, PAM
and PACIC instruments; these Veterans were included in
the final analyses.
The average age of our sample was 67.7 years (SD=11.3)
and respondents were predominantly male (95.1%). A
majority of respondents (70.4%) self-reported their
race/ethnicity as non-Hispanic white. Approximately
23.3% reported completion of a college degree or higher
level of education. Nearly 67.0% of respondents reported
having three or more chronic conditions. Almost all
respondents (99.8%) reported having one or more recent
outpatient visits. Approximately 81.3% of respondents
reported that they had seen a VA doctor or visited a VA
health care facility in the six-month period preceding
receipt of the survey (August 2012-February 2013). A
majority of respondents (87.2%) reported long-term PPI
use; and 53.1% had high total daily dose initial PPI
prescriptions. Sample characteristics are presented in Table
1.
The mean COMRADE score measuring patient
experiences with risk communication was 55.3 (SD=19.0);
the mean score measuring patient experiences with
decision-making was 61.0 (SD=17.3). Higher scores were
generally achieved in the decision-making effectiveness
subscale compared with the risk communication subscale.
Within the decision-making subscale, highest scores
(indicating more effective shared decision-making) were
noted in items that asked about the extent to which
respondents felt they could easily discuss their medical
condition with their doctor (3.90, SD=1.24) and their level
of confidence in treatment decisions that were made with
their doctor (3.72, SD=1.27). Within the risk
communication subscale, highest scores (denoting more
effective information exchanges between patients and
providers around treatment risks and benefits) were found

151

Patient-centered care and gastroesophageal reflux disease, Balbale et. al

Table 1. Sample characteristics

Characteristic
Age (n = 438)
mean (range, standard deviation)
Sex (n = 444)
Male
Female
Race (n = 439)
White
Black
Hispanic
Asian
Hawaiian / Pacific Islander
Ethnicity (n = 430)
Hispanic
Non-Hispanic
Education (n = 442)
Some or no college
College Graduate
Average distance from VA (miles) (n = 444)
mean (range, standard deviation)
Recent doctor or hospital visits in last 6 months (n = 444)
Yes, VA
Yes, non-VA
No
Characteristic
Number of chronic conditions (n = 444)
1-2
3 or more
Number of inpatient discharges (n = 444)
mean (range, standard deviation)
Length of stay a (n = 57)
Mean (range, standard deviation)
Number of 24-hour observation stays (n = 444)
mean (range, standard deviation)
Emergency room visits (n = 444)
mean (range, standard deviation)
Outpatient visits (n = 444)
mean (range, standard deviation)
a
Among those who had an inpatient discharge.
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Mean (SD) or Percent

67.74 (31 – 93, SD=11.33)
95.05
4.95
70.39
20.50
7.97
0.68
0.46
8.14
91.86
76.70
23.30
30.66 (0.12 – 314, SD=33.7)
81.31
24.10
4.05
Mean (SD) or Percent
33.11
66.89
0.22 (0 – 5, SD=0.67)
9.14 (1 – 48, SD=10.59)
0.04 (0 – 4, SD=0.29)
0.60 (0 – 12, SD=1.51)
24.0 (0 – 234, SD=22.27)
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specifically in items that addressed the extent to which
patients felt they knew the advantages (3.84, SD=1.19) and
disadvantages (3.88, SD=1.17) associated with treatment.
Lowest scores were within the risk communication
subscale. These items asked respondents to comment on
the degree to which they felt their doctor had given them a
chance to decide which treatment was best for themselves
(3.35, SD=1.39), and the degree to which they felt their
doctor had given them enough information about the
various treatment options available (3.43, SD=1.36). Item
responses for the COMRADE are presented in Table 2.

The mean overall PAM score was 56.1 (SD=19.2).
Approximately 47.8% of respondents were in the first and
second stages of activation, indicating disengaged patients
lacking confidence and knowledge to manage their health.
Specifically, 28.4% were categorized in the first stage, and
19.4% in the second. We found that 52.3% of respondents
were in the third and fourth stages of activation,
representing activated, goal-oriented patients who maintain
self-management, and effectively engage with health care
teams. Approximately 27.8% of respondents were
classified in the third stage of patient activation, and 24.8%
in the fourth stage. Highest scores were achieved in items
that asked respondents about the extent to which they felt

Table 2. COMRADE Item Scores
Mean (range)
COMRADE Item

Standard Deviation
(n=444)

1.

The doctor made me aware of the different treatments available

3.45 (1.0 – 5.0) 1.31

2.

The doctor gave me the chance to express my opinions about the different treatments

3.44 (1.0 – 5.0)1.34

available
3.

The doctor gave me the chance to ask for as much information as I needed about the

3.46 (1.0 – 5.0) 1.38

different treatment choices available
4.

The doctor gave me enough information about the treatment choices available

3.43 (1.0 – 5.0) 1.36

5.

The doctor gave enough explanation of the information about the treatment choices

3.44 (1.0 – 5.0) 1.33

6.

The information given to me was easy to understand

3.58 (1.0 – 5.0) 1.27

7.

I know the advantages of treatment or not having treatment

3.84 (1.0 – 5.0) 1.19

8.

I know the disadvantages of treatment or not having treatment

3.88 (1.0 – 5.0) 1.17

9.

The doctor gave me a chance to decide which treatment I thought was best for me

3.35 (1.0 – 5.0) 1.39

10. The doctor gave me a chance to be involved in the decisions during the consultation

3.47 (1.0 – 5.0) 1.40

11. Overall, I am satisfied with the information I was given

3.61 (1.0 – 5.0) 1.27

12. My doctor and I agreed about which treatment (or no treatment) was best for me

3.62 (1.0 – 5.0) 1.33

13. I can easily discuss my condition again with my doctor

3.90 (1.0 – 5.0) 1.24

14. I am satisfied with the way in which the decision was made in the consultation

3.71 (1.0 – 5.0) 1.29

15. I am sure that the decision made was the right one for me personally

3.71 (1.0 – 5.0) 1.27

16. I am satisfied that I am adequately informed about the issues important to the decision

3.70 (1.0 – 5.0) 1.24

17. It’s clear which choice is best for me

3.64 (1.0 – 5.0) 1.28

18. I’m aware of the treatment choices I have

3.63 (1.0 – 5.0) 1.29

19. I feel an informed choice has been made

3.66 (1.0 – 5.0) 1.27

20. The decision shows what is most important for me

3.70 (1.0 – 5.0) 1.25
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that they are the person who is responsible for managing
their own health condition (3.34, SD=0.64), and the extent
to which they believed that taking an active role in their
own health care was the most important factor in
determining their health and ability to function (3.42,
SD=0.56). Lowest scores were noted in items that focused
on respondents’ confidence in determining solutions when
new problems occur with their health (2.60, SD=0.67), and
their confidence in maintaining lifestyle changes, including
diet and exercise, during times of stress (2.78, SD=0.69).
Item responses for the PAM are shown in Table 3.
The mean PACIC summary score was 3.03 (SD=1.2).
Respondents achieved highest scores in the Delivery

System Design/Decision Support (3.38, SD=1.2) and
Patient Activation subscales (3.26, SD=1.3). Within these
subscales, items with the highest scores included those that
asked respondents about the extent to which they were
encouraged to talk about any problems with their
medicines or their effects (3.45, SD=1.36); the extent to
which they were satisfied that their chronic care was wellorganized (3.72, SD=1.19); and the extent to which
respondents were shown how steps they took to take care
of their health influenced their chronic condition (3.32,
SD=1.34). Lowest scores were in the Followup/Coordination (2.58, SD=1.3) and Goal
Setting/Tailoring subscales (2.98, SD=1.3). Within these
subscales, lowest scores were specifically noted in items

Table 3. PAM Item Scores
Mean (range)
PAM Item

Standard Deviation
(n=444)

1.

When all is said and done, I am the person who is responsible for taking care of my

3.34 (1.0 – 5.0) 0.64

health (n=443)
2.

Taking an active role in my own health care is the most important thing that affects

3.42 (1.0 – 5.0) 0.56

my health (n=440)
3.

I am confident I can help prevent or reduce problems associated with my health

3.13 (1.0 – 5.0) 0.63

(n=439)
4.

I know what each of my prescribed medications do (n=441)

3.10 (1.0 – 5.0) 0.66

5.

I am confident that I can tell whether I need to go to the doctor or whether I can

3.06 (1.0 – 5.0) 0.66

take care of a health problem myself (n=441)
6.

I am confident that I can tell a doctor concerns I have even when he or she does not

3.18 (1.0 – 5.0) 0.65

ask (n=440)
7.

I am confident that I can follow through on medical treatments I may need to do at

3.25 (1.0 – 5.0) 0.59

home (n=441)
8.

I understand my health problems and what causes them (n=439)

3.01 (1.0 – 5.0) 0.69

9.

I know what treatments are available for my health problems (n=441)

2.87 (1.0 – 5.0) 0.70

10.

I have been able to maintain (keep up with) lifestyle changes, like eating right or

2.87 (1.0 – 5.0) 0.71

exercising (n=443)
11.

I know how to prevent problems with my health (n=433)

2.92 (1.0 – 5.0) 0.62

12.

I am confident I can figure out solutions when new problems arise with my health

2.60 (1.0 – 5.0) 0.67

(n=438)
13.

I am confident that I can maintain lifestyle changes, like eating right and exercising,

2.78 (1.0 – 5.0) 0.69

even during times of stress (n=443)
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that addressed the extent to which respondents were asked
how their visits with other doctors were going (2.60,
SD=1.53); the extent to which respondents were
encouraged to attend programs in their community that
could help them (2.24, SD=1.44); and the extent to which
respondents were encouraged to go to specific groups or
classes to help them better cope with their chronic
condition (2.78, SD=1.54). Item responses for the PACIC
are included in Table 4.

Discussion
To our knowledge, this is the first study to evaluate patient
perceptions of PCC in a national sample of Veterans with
GERD on PPI therapy. Using three validated PRO
measures to assess PCC, we learned that perceptions of
care among patients with GERD on PPI therapies were
generally high and favorable overall. Patients reported that
care was well-organized, supportive in enhancing their
decision-making, and effective in improving their
understanding of care. However, our findings also reveal
several potential areas of improvement that can be

Table 4. PACIC Item Scores
Mean (range)
PACIC Item

Standard Deviation
(n=444)

1.

Asked for my ideas when we made a treatment plan (n=434)

3.11 (1.0 - 5.0) 1.37

2.

Given choices about treatment to think about (n=428)

3.24 (1.0 – 5.0) 1.37

3.

Asked to talk about any problems with my medicines or their effects (n=431)

3.45 (1.0 – 5.0) 1.36

4.

Given a written list of things I should do to improve my health (n=438)

3.09 (1.0 – 5.0) 1.43

5.

Satisfied that my care was well organized (n=434)

3.72 (1.0 – 5.0) 1.19

6.

Shown how what I did to take care of myself influenced my condition (n=434)

3.36 (1.0 – 5.0) 1.34

7.

Asked to talk about my goals in caring for my condition (n=434)

2.95 (1.0 – 5.0) 1.43

8.

Helped to set specific goals to improve my eating or exercise (n=434)

3.02 (1.0 – 5.0) 1.43

9.

Given a copy of my treatment plan (n=432)

3.02 (1.0 – 5.0) 1.52

10. Encouraged to go to a specific group or class to help me cope with my chronic

2.78 (1.0 – 5.0) 1.54

condition (n=434)
11. Asked questions, either directly or on a survey, about my health habits (n=436)

3.13 (1.0 – 5.0) 1.44

12. Sure that my doctor or nurse thought about my values, beliefs, and traditions when

3.41 (1.0 – 5.0) 1.43

they recommended treatments to me (n=436)
13. Helped to make a treatment plan that I could carry out in my daily life (n=434)

3.30 (1.0 – 5.0) 1.44

14. Helped to plan ahead so I could take care of my condition even in hard times

3.08 (1.0 – 5.0) 1.51

(n=436)
15. Asked how my chronic condition affects my life (n=436)

3.20 (1.0 – 5.0) 1.49

16. Contacted after a visit to see how things were going (n=439)

2.62 (1.0 – 5.0) 1.53

17. Encouraged to attend programs in the community that could help me (n=433)

2.24 (1.0 – 5.0) 1.44

18. Referred to a dietician, health educator, or counselor (n=438)

2.61 (1.0 – 5.0) 1.50

19. Told how my visits with other types of doctors, like an eye doctor or other specialist,

2.82 (1.0 – 5.0) 1.53

helped my treatment (n=439)
20. Asked how my visits with other doctors were going (n=438)
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addressed to optimize delivery of PCC and increase ratings
of care within this patient population. Nearly half of the
sample was characterized by lower levels of patient
activation. Moreover, our data demonstrate gaps that may
exist in delivering follow-up care, enabling patients to set
specific goals related to their health, and informing
patients about the risks and benefits associated with
available treatment options for GERD.
The overarching mission of the PCC model includes
delivering high-quality care that is responsive to individual
needs, supporting patient engagement in clinical care, and
improving communication between patients and the health
care system.24, 40 Given the overlap between PCC and
patient experience principles,26 PRO measures that address
PCC concepts may represent an important component to
assess patient experiences and capture the perspectives of
patients with burdensome, prevalent, and costly diseases. 41
Despite their value in evaluating care across a range of
chronic conditions,42-44 the application of the PROs used
in this study has not been previously explored in the area
of GERD and remains limited within the broader
gastrointestinal (GI) literature. Randell and colleagues45
previously used the PACIC to assess care perceptions
among individuals with inflammatory bowel disease (IBD),
finding that respondents achieved lowest scores in the
follow-up and coordination of care subscale. This is
corroborated by our study, as well as several prior studies
describing PACIC scores beyond GI diseases,46-49 and
suggests that continuity of care is an important goal for
quality improvement in GERD care. In prior studies
exploring patient activation among individuals with IBD
and irritable bowel syndrome (IBS), respondents achieved
similar PAM scores compared to our sample. 50-51 Given
the chronic nature of GERD symptoms and a need for
these patients to remain actively engaged throughout the
care continuum, the PAM may be especially useful to
identify patients with GERD who require additional
support to manage their own health in contrast to
activated patients who may be well-suited for selfmanagement interventions alone.
Although our results delineate several existing strengths
and gaps in the patient experience for Veterans with
GERD, recent recommendations highlight a need to
optimize use of PROs and translate PRO data into
improved clinical practice.52 Our findings present a
number of clinical implications and actionable next steps
unique to the care of patients with GERD on PPI therapy.
These PRO data can inform how the health care system
can better support patients with GERD, including better
understanding and enhancing patient activation, risk
communication, and follow-up care. One key finding that
emerged as a potential deficit within GERD care was the
perceived risk communication related to GERD
treatments. Despite their benefits to many patients, there
is accumulating evidence around a broad range of risks
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and side effects associated with PPI use.18 More recently,
widespread press coverage linking PPI use to dementia
and chronic kidney disease have led to growing fears and
concerns among PPI users.25, 53-54 Our findings underscore
these concerns, and suggest that providers may need to
pay particular attention to patients’ concerns and better
inform patients of the risks and benefits related to PPIs
and other GERD therapies. No prior studies have
addressed patient experiences or communication in
GERD care; however, in a study of outpatient care
experiences in a broader GI patient population, Larkins et
al found that GI patients perceived the quality of patientprovider interaction to be integral to an optimal patient
experience.55 This may be especially important to consider
among GERD patients. Quality improvement efforts may
benefit from further engaging patients to determine how
patient-provider communication and care processes can be
enhanced to address patient concerns and preferences.
Several limitations should be acknowledged. Our survey
response rate was lower than expected and may not
represent the greater Veteran population with GERD.
Moreover, Veterans represent a population that is
generally older and less educated compared to the
American population overall;56 thus, our results may not
be applicable to the broader population with GERD who
use PPIs. The cross-sectional study design allowed us to
examine patient perceptions at a given point of time only.
Finally, the self-reported nature of our survey data may
have introduced additional limitations.
We contribute to existing literature by (1) using PROs to
describe how patients with GERD on PPI therapy
perceive care, and (2) harnessing patient perspectives that
can be used to optimize care experiences to better align
with the unique needs and preferences within this
population. Our approach may be used by researchers and
clinicians to characterize patient experiences among
individuals with other chronic diseases beyond GERD. In
this study, Veterans with GERD perceived care to be wellorganized, supportive in enhancing shared decisionmaking, and effective in improving their understanding of
care. However, several gaps may exist in delivering GERD
follow-up care, enhancing patient activation, and
informing patients about the risks and benefits of existing
treatments. Findings can inform further investigation and
development of targeted interventions to enhance the
experience of PCC for patients with GERD. Further
studies are needed to understand patient- and system-level
factors independently associated with higher scores in
some PCC domains, including shared decision-making and
delivery system design, and lower scores in other domains,
including risk communication and follow-up care. Efforts
are also needed to explore if PCC outcomes are associated
with GERD symptom control, particularly in areas of
follow-up support, care coordination and risk
communication. This may impact appropriate use of
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diagnostic testing and long-term medication use for an
increasingly large, complex patient population.

Acknowledgement
The views expressed in this manuscript are those of the
authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs or the
United States Government.
Specific author contributions: Sherri LaVela, Andrew
Gawron and Salva Balbale planned and conducted the
study. Salva Balbale and Andrew Gawron analyzed data.
Salva Balbale drafted the initial form and all revisions of
this manuscript. All authors reviewed and approved the
final manuscript draft submitted.
Financial support: This study was funded by the
Department of Veterans Affairs, Office of PatientCentered Care and Cultural Transformation and the Office
of Research and Development Health Services Research
and Development, Quality Enhancement Research
Initiative (PEC-13-002; PI: LaVela).

References
1.
2.
3.
4.

5.
6.
7.

8.

9.
10.

El-Serag HB, Sweet S, Winchester CC, et al. Update
on the epidemiology of gastro-oesophageal reflux
disease: A systematic review. Gut. 2014;63:871-880.
Rubenstein JH, Chen JW. Epidemiology of
gastroesophageal reflux disease. Gastroenterol Clin
North Am. 2014;43:1-14.
Peery AF, Dellon ES, Lund J, et al. Burden of
gastrointestinal disease in the United States: 2012
update. Gastroenterol. 2012;143:1179-1187.
Vakil N, van Zanten SV, Kahrilas P, et al. The
Montreal definition and classification of
gastroesophageal reflux disease: A global evidencebased consensus. Am J Gastroenterol. 2006;101:19001920.
Ronkainen J, Agréus L. Epidemiology of reflux
symptoms and GORD. Best Prac Res Clin
Gastroenterol. 2013;27:325-337.
Wiklund I. Review of the quality of life and burden
of illness in gastroesophageal reflux disease. Dig Dis
Sci. 2004;22:108-114.
Fass R, Ofman JJ. Gastroesophageal reflux disease—
should we adopt a new conceptual framework? A
new conceptual framework for GERD. Am J
Gastroenterol. 2002;97:1901-1909.
Lee S, Lien H, Lee T, et al. Heartburn and
regurgitation have different impacts on life quality of
patients with gastroesophageal reflux disease. World J
Gastroenterol. 2014;20:12277-12282.
Katz PO, Gerson LB, Vela MF. Guidelines for the
diagnosis and management of gastroesophageal
reflux disease. Am J Gastroenterol. 2013;108:308-28.
Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American
Gastroenterological Association institute technical

Patient Experience Journal, Volume 5, Issue 3 – 2018

11.

12.

13.

14.

15.

16.
17.
18.
19.

20.

21.
22.
23.

24.
25.

review on the management of gastroesophageal
reflux disease. Gastroenterol. 2008;135:1392-1413.
Yadlapati R, Gawron AJ, Bilimoria K, et al.
Development of quality measures for the care of
patients with gastroesophageal reflux disease. Clin
Gastroenterol Hepatol. 2015;13:874-883.
Gikas A, Triantafillidis JK. The role of primary care
physicians in early diagnosis and treatment of
chronic gastrointestinal diseases. Int J Gen Med.
2014;7:159.
Hungin APS, Hill C, Molloy–Bland M, et al.
Systematic review: Patterns of proton pump
inhibitor use and adherence in gastroesophageal
reflux disease. Clin Gastroenterol Hepatol. 2012;10:109116.
Gawron AJ, Pandolfino JE, Miskevics S, et al.
Proton pump inhibitor prescriptions and subsequent
use in US Veterans diagnosed with gastroesophageal
reflux disease. J Gen Intern Med. 2013;28:930-937.
Gawron AJ, Rothe J, Fought AJ, et al. Many patients
continue using proton pump inhibitors after negative
results from tests for reflux disease. Clin Gastroenterol
Hepatol. 2012;10:620-625.
Corleto VD, Festa S, Di Giulio E, et al. Proton
pump inhibitor therapy and potential long-term
harm. Curr Opin Endocrinol Diabetes Obes. 2014;21:3-8.
Yang Y, Lewis JD, Epstein S, et al. Long-term
proton pump inhibitor therapy and risk of hip
fracture. J Am Med Assoc. 2006;296:2947-2953.
Sheen E, Triadafilopoulos G. Adverse effects of
long-term proton pump inhibitor therapy. Dig Dis
Sci. 2011;56:931-950.
Gawron AJ, French DD, Pandolfino JE, et al.
Economic evaluations of gastroesophageal reflux
disease medical management. Pharmacoeconomics.
2014;32:745-758.
van Zanten SJ, Henderson C, Hughes N. Patient
satisfaction with medication for gastroesophageal
reflux disease: A systematic review. Can J
Gastroenterol. 2012;26:196-204.
Jackson GL, Powers BJ, Chatterjee R, et al. The
patient-centered medical home: A systematic review.
Ann Intern Med. 2013;158:169-178.
Wagner EH, Groves T. Care for chronic diseases. Br
Med J. 2002;325:913-914.
Patel NK, Jaén CR, Stange KC, et al. Patient
centered medical home: A journey not a destination.
In Malone ML, Capezuti EA, Palmer RM (eds).
Geriatrics Models of Care: Bringing 'Best Practice' to
an Aging America. Springer International Publishing:
Switzerland, 2015, pp.155-162.
Epstein RM, Street Jr RL. The values and value of
patient-centered care. Ann Fam Med. 2011;9:100-103.
Laine L, Nagar A. Long-term PPI use: Balancing
potential harms and documented benefits. Am J
Gastroenterol. 2016;111:913–915.

157

Patient-centered care and gastroesophageal reflux disease, Balbale et. al

26.
27.

28.
29.

30.
31.

32.

33.
34.

35.

36.

37.

38.

39.

40.

158

Wolf J, Niederhauser V, Marshburn D, LaVela S.
Defining patient experience: a critical decision for
healthcare organizations. Patient Exp J. 2014;1:3-19.
Wolf J. The patient experience: Strategies and
approaches for providers to achieve and maintain a
competitive advantage. Bedford, TX: The Beryl
Institute. 2013.
LaVela SL, Gallan AS. Evaluation and measurement
of patient experience. Patient Exp J. 2014;1: 28–36.
Yano EM, Bair MJ, Carrasquillo O, et al. Patient
aligned care teams (PACT): VA’s journey to
implement patient-centered medical homes. J Gen
Intern Med. 2014;29:547-549.
Schwenk TL. The patient-centered medical home:
One size does not fit all. J Am Med Assoc.
2014;311:802-803.
Perry KA, Pham TH, Spechler SJ, et al. 2014 SSAT
state-of-the-art conference: Advances in diagnosis
and management of gastroesophageal reflux disease.
J Gastrointestinal Surg 2015;19:458-466.
Vakil NB, Halling K, Becher A, et al. Systematic
review of patient-reported outcome instruments for
gastroesophageal reflux disease symptoms. Eur J
Gastroenterol Hepatol. 2013;25:2-14.
Dillman DA, Smyth JD, Christian LM. Internet,
Mail, and Mixed-Mode Surveys: the Tailored Design
Method. Hoboken, NJ: Wiley; 2009.
Elwyn G, Edwards A, Kinnersley P, et al. Shared
decision making and the concept of equipoise: the
competences of involving patients in healthcare
choices. Br J Gen Pract. 2000;50:892-9.
Edwards A, Elwyn G, Hood K, et al. The
development of COMRADE—a patient-based
outcome measure to evaluate the effectiveness of
risk communication and treatment decision making
in consultations. Patient Educ Couns. 2003;50:311-22.
Hibbard JH, Stockard J, Mahoney ER, et al.
Development of the Patient Activation Measure
(PAM): conceptualizing and measuring activation in
patients and consumers. Health Serv Res.
2004;39:1005-26.
Hibbard JH, Mahoney ER, Stockard J, et al.
Development and testing of a short form of the
patient activation measure. Health Serv Res.
2005;40:1918-30.
Glasgow RE, Wagner EH, Schaefer J, et al.
Development and validation of the patient
assessment of chronic illness care (PACIC). Med
Care. 2005;43:436-44.
Schmittdiel J, Mosen D, Glasgow RE, et al. Patient
Assessment of Chronic Illness Care (PACIC) and
improved patient-centered outcomes for chronic
conditions. J Gen Intern Med. 2008; 23:77–80.
Institute of Medicine. Crossing the quality chasm: A
new health system for the 21st century. Washington,
DC: The National Academies Press; 2001.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.

53.

Snyder CF, Jensen RE, Segal JB, et al. Patientreported outcomes (PROs): Putting the patient
perspective in patient-centered outcomes research.
Med Care. 2013;51:S73.
Glasgow RE, Whitesides H, Nelson CC, et al. Use of
the Patient Assessment of Chronic Illness Care
(PACIC) with diabetic patients relationship to
patient characteristics, receipt of care, and selfmanagement. Diabetes Care. 2005;28:2655–61.
Bonomi AE, Wagner EH, Glasgow RE, et al.
Assessment of chronic illness care (ACIC): A
practical tool to measure quality improvement.
Health Serv Res. 2002;37:791–820.
Boult C, Reider L, Frey K, et al. Early effects of
guided care on the quality of health care for
multimorbid older persons: A cluster-randomized
controlled trial. J Gerontol A Biol Sci Med Sci.
2008;63:321–7.
Randell RL, Long MD, Martin CF, et al. Patient
perception of chronic illness care in a large
inflammatory bowel disease cohort. Inflamm Bowel
Dis. 2013;19:1428.
Jackson GL, Weinberger M, Hamilton NS, et al.
Racial/ethnic and educational-level differences in
diabetes care experiences in primary care. Prim Care
Diabetes. 2008;2:39–44.
Rosemann T, Laux G, Szecsenyi J, et al. The Chronic
Care Model: Congruency and predictors among
primary care patients with osteoarthritis. Qual Saf
Health Care. 2008; 17:442–446.
Schmittdiel J, Mosen DM, Glasgow RE, et al. Patient
Assessment of Chronic Illness Care (PACIC) and
improved patient-centered outcomes for chronic
conditions. J Gen Intern Med. 2008; 23:77–80.
Szecsenyi J, Rosemann T, Joos S, et al. German
diabetes disease management programs are
appropriate for restructuring care according to the
chronic care model: an evaluation with the Patient
Assessment of Chronic Illness Care instrument.
Diabetes Care. 2008;31:1150–1154.
Dorn SD, Palsson OS, Woldeghebriel M, et al.
Development and pilot testing of an integrated, web‐
based self‐management program for irritable bowel
syndrome (IBS). Neurogastroenterol & Motil.
2015;27:128-134.
Munson GW, Wallston KA, Dittus RS, et al.
Activation and perceived expectancies: correlations
with health outcomes among veterans with
inflammatory bowel disease. J Gen Intern Med.
2009;24:809-815.
Almario CV, Chey WD, Khanna D, et al. Impact of
National Institutes of Health gastrointestinal
PROMIS measures in clinical practice: Results of a
multicenter controlled trial. Am J Gastroenterol. 2016;
advance online publication.
Gomm W, von Holt K, Thomé F, et al. Association
of proton pump inhibitors with risk of dementia: A

Patient Experience Journal, Volume 5, Issue 3 – 2018

Patient-centered care and gastroesophageal reflux disease, Balbale et. al

54.
55.

56.

pharmacoepidemiological claims data analysis. J Am
Med Assoc Neurol. 2016;73:410-6.
Lazarus B, Chen Y, Wilson FP, et al. Proton pump
inhibitor use and the risk of chronic kidney disease. J
Am Med Assoc Intern Med. 2016;176:238-46.
Larkins AS, Windsor AV, Trebble TM. An
evaluation of patient attitudes to the
gastroenterology outpatient experience. Euro
Gastroenterol Hepatol. 2013;25:44-5.
Morgan RO, Teal CR, Reddy SG, et al. Measurement
in Veterans Affairs health services research: Veterans
as a special population. Health Serv Res.
2005;40:1573–1583.

Patient Experience Journal, Volume 5, Issue 3 – 2018

159

